US OptionsDetailed Quotes

PBH250117C85000

Watchlist

2.96
0.000.00%

15min DelayTrading Dec 4 14:55 ET

0.00High0.00Low

Prestige Consumer Healthcare Stock Discussion

Moomoo AI

Mar 26, 2024 09:08

Investors seem to focus more on the company's revenue growth despite the decrease in earnings per share. The company's long-term track record of an annual TSR of 20% over five years makes it a business worth watching.

Those Who Invested in Prestige Consumer Healthcare (NYSE:PBH) Five Years Ago Are up 144%

Moomoo AI

Mar 5, 2024 07:39

Investors may be expecting a turnaround in the company's lackluster revenue performance, hence the moderate P/S ratio. However, the company's muted revenue growth estimates compared to the industry make its current P/S ratio unexpected. A positive change is needed to justify this ratio.

Some Shareholders Feeling Restless Over Prestige Consumer Healthcare Inc.'s (NYSE:PBH) P/S Ratio

Moomoo AI

Feb 11, 2024 07:43

Prestige Consumer Healthcare's revenue growth is predicted to slow, with an estimated annual growth rate of 1.9% until 2025, significantly below the historical 4.2% p.a. growth. Compared to industry peers forecasted to grow at 9.0% per year, Prestige is expected to lag behind.

Here's What Analysts Are Forecasting For Prestige Consumer Healthcare Inc. (NYSE:PBH) After Its Third-Quarter Results

Moomoo AI

Jan 30, 2024 12:35

An insider selling shares below the current price may suggest they deemed the lower price fair, questioning their view of the recent higher valuation. However, this is a weak sign as it doesn't imply insiders think the shares are fully valued. The level of insider ownership indicates a reasonable alignment with shareholder interests.

This Prestige Consumer Healthcare Insider Reduced Their Stake By 57%

Moomoo Breakfast US

May 10, 2022 07:18

Columns Today's pre-market stock movers: PTON, NVAX, AMC, SONY and more

Gainers:
• $Biohaven (BHVN.US)$ +70.3% (Biohaven Pharmaceutical and Pfizer (PFE) announce that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven)
• $Vroom (VRM.US)$ +33.3% (also CEO Paul Hennessy steps down; Tom Shortt appointed as CEO)
• $Nuvve (NVVE.US)$ +10.2% (NVVE and CENN announce alliance to offer electrification solution for commercial fleets)
• $ShockWave Medical (SWAV.US)$ +14.6% (I...

Analysts Notebook

May 10, 2022 05:45

Columns Top upgrades and downgrades on 5/10

Upgrades
• $Autoliv (ALV.US)$ : UBS Upgrades to Buy from Neutral - PT $90 (from $103)
• $Clean Energy Fuels (CLNE.US)$ : Raymond James Upgrades to Outperform from Market Perform - PT $6
• $EOG Resources (EOG.US)$ : Raymond James Upgrades to Strong Buy from Outperform - PT $170
• $Genuine Parts (GPC.US)$ : BofA Securities Upgrades to Neutral from Underperform - PT $133
• $Graphic Packaging (GPK.US)$ : Exane Upgrades to Outperform from Neutral - PT $26
• $Healthcare Trust of America Inc (HTA.US)$ : Berenbe...

Analysts Notebook

May 9, 2022 05:50

Columns Top upgrades and downgrades on 5/9

Upgrades
• $Cigna Group (CI.US)$ : Cowen Upgrades to Outperform from Market Perform - PT $329 (from $242)
• $DLocal (DLO.US)$ : New Street Research Upgrades to Buy from Neutral - PT $38
• $Goodyear Tire & Rubber (GT.US)$ : CFRA Upgrades to Buy from Hold - PT $20 (from $24)
• $Match group (MTCH.US)$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $115 (from $140)
• $Prestige Consumer Healthcare (PBH.US)$ : Oppenheimer Upgrades to Outperform from Perform - P...

Analysts Notebook

Mar 25, 2022 06:42

Columns Top upgrades and downgrades on 3/25

Upgrades
• $Farfetch (FTCH.US)$: Societe Generale Upgrades to Buy from Hold - PT $22
• $Teva Pharmaceutical Industries (TEVA.US)$ : Bernstein Upgrades to Outperform from Market Perform - PT $11
Downgrades
• $ASML Holding (ASML.US)$ : Redburn Downgrades to Sell from Neutral
• $AutoWeb (AUTO.US)$ : Lake Street Capital Markets Downgrades to Hold from Buy - PT $2.50
• $Axalta Coating Systems (AXTA.US)$ : RBC Capital Downgrades to Sector Perform from Outperform - PT $...

No comment yet